Abstracts tagged "longitudinal studies"

Abstract Number: 1408 • ACR Convergence 2024
Color Doppler Ultrasound Is a Reliable Method for Imaging the Lacrimal Glands in Patients with Suspected Sjögren’s Disease
Ting Yang¹, Neils Sluijpers¹, Jolien van Nimwegen¹, Alja Stel¹, Adriaan Coumou¹, Frans Kroese², Hendrika Bootsma³, Konstantina Delli¹ and Sarah Pringle², ¹UMCG, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands
Background/Purpose: As a widely available, non-invasive and repeatable technique, ultrasound has already been used for the examination of irregularities of the major salivary glands. However,…
Abstract Number: 2490 • ACR Convergence 2024
Longitudinal Kidney Function Trajectories in Patients Enrolled in the Plasma Exchange and Glucocorticoids in ANCA-Associated Vasculitis Trial
Jennifer Hanberg¹, Yuqing Zhang², Andreas Kronbichler³, Anna Matyjek⁴, Carol McAlear⁵, Balazs Odler⁶, Lisa Uchida⁷, Duvuru Geetha⁸, Carmel Hawley⁹, David Jayne⁷, Michael walsh¹⁰, Peter Merkel⁵ and Zachary Wallace¹¹, and the PEXIVAS investigators, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Medical University Innsbruck and University of Cambridge, Innsbruck, Austria, ⁴Medical University of Lodz and Medical University Innsbruck, Lodz, Poland, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Medical University of Graz, Graz, Austria, ⁷University of Cambridge, Cambridge, United Kingdom, ⁸Johns Hopkins University, Baltimore, MD, ⁹Princess Alexandra Hospital and Translational Research Institute, Brisbane, Australia, ¹⁰McMaster University, Hamilton, ON, Canada, ¹¹Massachusetts General Hospital, Newton, MA
Background/Purpose: ANCA-associated vasculitis (AAV) causes kidney damage, leading to a spectrum of chronic kidney disease (CKD) and end-stage kidney disease (ESKD). Clinically distinct kidney function…
Abstract Number: 1412 • ACR Convergence 2024
Survival and Predictive Markers of Prognosis in Patients with Cancer Occurrence After Sjögren Syndrome: A Long-term Observational Study
Yezi Peng¹, Jiana Chen², Yafei Ren³, Dan Yang², Xiangyi Shen⁴, Xu Jiang⁵ and Huaxia Yang², ¹Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Dong Cheng Qu, Beijing, China (People's Republic), ²Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Department of Rheumatology and immunotogy,Affiliated Hospital of Guilin Medical University,Guilin, China, Guangxi, China (People's Republic), ⁴Tsinghua University, Beijing, China, ⁵National Infrastructure for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Background/Purpose: Patients with Sjögren syndrome (SS) have been reported to have a higher risk of cancer than the general population, and malignancy constitutes one of…
Abstract Number: 2509 • ACR Convergence 2024
Bone Marrow Failure in VEXAS Is Associated with the Degree of UBA1b Deficiency
Benjamin Turturice¹, Alice Fike¹, Bhavisha Patel², Emma Groarke², Karyssa Stonick¹, Shanni Liu¹, Wendy Goodspeed¹, Kaitlin Quinn¹, Neal Young² and Peter Grayson³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: VEXAS is a multisystem autoinflammatory disorder due to somatic mutations in UBA1. The disease is characterized by ineffective hematopoiesis with increased risk of transfusion…
Abstract Number: 1494 • ACR Convergence 2024
Trajectories of Disease Evolution upon Treatment Initiation in Systemic Lupus Erythematosus: Pooled Results from Three Randomized Clinical Trials of Belimumab
Ioannis Parodis¹, Julius Lindblom², Alexandre Tsoi³, Dionysis Nikolopoulos⁴ and Lorenzo Beretta⁵, ¹Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institute, Stockholm, Sweden, ⁴Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁵Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy
Background/Purpose: The efficacy of belimumab in treating SLE has been demonstrated in several phase 3 randomized clinical trials (RCTs). These trials showed belimumab efficacy on…
Abstract Number: 2555 • ACR Convergence 2024
Addressing Economic Insecurities Could Improve Patient-Reported Outcomes in Lupus
Shivani Garg¹, Jay Patel¹, Meredith Ingersoll², Shelby Gomez², Amanda Weber², Sarah Panzer¹, Sancia Ferguson³, Tripti Singh¹ and Christie Bartels⁴, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²UW Health, Madison, ³University of Wisconsin, Madison, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: A complex interaction between biologic factors and social determinants of health (SDoH) drives disparities in lupus (or SLE) outcomes in the US. A recent…
Abstract Number: 1539 • ACR Convergence 2024
Effectiveness & Safety of Early versus Late Use of Rituximab in Extra-renal Lupus: Real World Experience from a Tertiary Care Centre
JOHN KUMAR DAS¹, ABHILASHA ARVIND MANWATKAR² and JOHN MATHEW², ¹Christian Medical College, Vellore, India, ²christian medical college, vellore, Tamil Nadu, India
Background/Purpose: Rituximab, a monoclonal antibody targeting CD20 positive B cells failed to show effectiveness in SLE, including EXPLORER and LUNAR trials.However, real world data in…
Abstract Number: 2571 • ACR Convergence 2024
Trajectories of Physical Function in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Clare Cunningham¹, Roberta A Berard², Matthew Berkowitz³, Brian Feldman⁴, Nicole Johnson⁵, Lillian Lim⁶, Thomas Loughin³, Meghan McPherson⁷, Paivi Miettunen⁵, Jean-Philippe Proulx-Gauthier⁸, Dax Rumsey⁶, Heinrike Schmeling⁵, Lori Tucker⁹, Kristin Houghton¹⁰ and Jaime Guzman¹¹, and CAPRI Registry Investigators, ¹University of British Columbia, Vancouver, BC, Canada, ²London Health Sciences Centre, London, ON, Canada, ³Simon Fraser University, Burnaby, BC, Canada, ⁴Division of Rheumatology, The Hospital for Sick Children; Departments of Pediatrics and Medicine, Faculty of Medicine; The Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶University of Alberta, Edmonton, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸CHU de Quebec - Universite Laval, Quebec, QC, Canada, ⁹BC Children's Hospital, Vancouver, BC, Canada, ¹⁰University of British Columbia - Vancouver, Vancouver, BC, Canada, ¹¹University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of childhood. Contrary to historical cohorts, it is hoped that with contemporary treatments…
Abstract Number: 0175 • ACR Convergence 2024
Do Knee Strength and Pain Relate to Developing Stair Climbing Difficulty for Knee Osteoarthritis?
Jason Jakiela¹, Yvonne Golightly², Sydney Liles³, Judy Foxworth⁴ and Daniel White⁵, ¹Winston-Salem State University, Winston-Salem, NC, ²University of Nebraska Medical Center, Omaha, NE, ³University of Delaware, Elkton, MD, ⁴Winston-Salem State University, Elon, NC, ⁵University of Delaware, Newark, DE
Background/Purpose: Knee osteoarthritis (OA) is a leading cause of functional limitation in older adults, and stair climbing difficulty is often the first-reported limitation. Previous work…
Abstract Number: 1541 • ACR Convergence 2024
Effect of Rituximab on Long-term Damage Acquisition in Patients with Systemic Lupus Erythematosus
Amanda Brito¹, Teresa Moitinho de Almeida², Sofia Miranda³, Miriam Barreto Baié¹, Daniel Calado³ and David Isenberg⁴, ¹Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil, ²Unidade Local de Saúde de Lisboa Ocidental, Lisboa, Portugal, ³Hospital do Divino Espírito Santo, Ponta Delgada, Portugal, ⁴University College London, London, United Kingdom
Background/Purpose: B-cell depletion has been used to treat patients with systemic lupus erythematosus (SLE) for over twenty years, but we still lack studies that evaluate…
Abstract Number: 0638 • ACR Convergence 2024
Soluble TNF RII in Lupus Nephritis as a Biomarker of Disease Activity and Treatment Response
Ranjan Gupta¹, Sonam Rajput², Jayanth Kumar² and Dipendra K Mitra², ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²All India Institute of Medical Sciences, New Delhi, New Delhi, India
Background/Purpose: Lupus Nephritis (LN) affects almost 60-70% patients of Systemic Lupus Erythematosus (SLE). Conventional markers of renal involvement i.e. proteinuria and renal biopsy have limitations…
Abstract Number: 1870 • ACR Convergence 2024
Costs and Healthcare Resource Utilization Associated with Inpatient and Day Hospitalizations of Patients with Lupus and Psychiatric Manifestations in France
Nicoleta Petrica¹, Nathan Cohen¹, Maria Pini¹, Minjee Park², Mathieu Rosé³ and Jean-Francois Ricci², ¹Alira Health, Paris, France, ²Alira Health, Basel, Switzerland, ³Alira Health, Barcelone, Spain
Background/Purpose: Lupus, a rare chronic autoimmune disorder, severely impacts patients' quality of life, productivity, and survival, placing a heavy burden on the healthcare system. Up…
Abstract Number: 0688 • ACR Convergence 2024
Mycophenolate Mofetil Treatment in Limited Cutaneous Systemic Sclerosis Reduces the Risk of Vascular Complication Leading to Treatment Escalation: Emulation of a Target Trial Using Time-dependent Propensity Score-matching
Enrico De Lorenzis¹, Gerlando Natalello², Fabio Cacciapaglia³, Rossella De Angelis⁴, Edoardo Cipolletta⁵, Veronica Codullo⁶, Giacomo De Luca⁷, Dilia Giuggioli⁸, Francesca Ingegnoli⁹, Valeria Riccieri¹⁰, Maria Antonietta D'Agostino¹¹, Clodoveo Ferri¹², Marco Matucci Cerinic¹³ and Silvia Laura Bosello¹⁴, ¹Catholic University of the Sacred Heart, Roma, Rome, Italy, ²Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, ³Rheumatology Unit � DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ⁴Polytechnic University of Marche, Ancona, Italy, Ancona, Italy, ⁵Polytechnic University of Marche, Ancona, Italy, ⁶Division of Rheumatology - Policlinico San Matteo, Pavia, Italy, Pavia, Lombardia, Italy, ⁷Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, ⁸Scleroderma Unit, University of Modena and Reggio Emilia, Modena, Italy, ⁹Division of Clinical Rheumatology, ASST Pini, Dept. of Clinical Sciences & Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Research Center for Environmental Health, Università degli Studi di Milano, Milan, Italy, ¹⁰Department of Rheumatology, La Sapienza University of Rome, Rome, Italy, ¹¹Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy, ¹²Rheumatology Unit, School of Medicine, University of Modena and Reggio Emilia, Modena, Italy, ¹³Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, ¹⁴Unit of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: The prescription of Mycophenolate Mofetil (MMF) represents the primary treatment for interstitial lung disease (ILD) associated with systemic sclerosis (SSc) and is an option…
Abstract Number: 1871 • ACR Convergence 2024
A Seropositive RA Polygenic Risk Score Does Not Predict Progression to RA in an ACPA Positive Population
Tada Vargas¹, Lauren Vanderlinden², Patrick Carry³, Kristen Demoruelle⁴, Marie Feser¹, Katerina Kechris⁵, Jane Buckner⁶, William Robinson⁷, Gary Firestein⁸, Michael Holers¹, Kevin Deane⁹ and Jill Norris¹⁰, ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Colorado School of Public Health, Monument, CO, ³Department of Orthopedics, University of Colorado School of Medicine, Aurora, CO, ⁴University of Colorado Anschutz Medical Campus, Golden, CO, ⁵Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶Benaroya Research Institute, Seattle, WA, ⁷Division of Immunology and Rheumatology, Stanford University, and VA Palo Alto Health Care System, Stanford, CA, ⁸University of California, San Diego, San Diego, CA, ⁹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹⁰Colorado School of Public Health, Denver, CO
Background/Purpose: Serum autoantibodies, such as ACPA and RF, are commonly detectable prior to the development of seropositive clinical RA; however, not all individuals with these…
Abstract Number: 0711 • ACR Convergence 2024
Molecular Signatures in the Skin as Predictors of Longitudinal Clinical Trajectories in Patients with Systemic Sclerosis
Natania Field¹, Monica Yang², Niket Gupta¹, Maxwell Shramuk¹, Lutfiyya Muhammad¹, Vivien Goh¹, Monica Espinoza³, Yiwei Yuan³, Rezvan Parvizi³, Kathleen Aren⁴, Mary Carns⁴, Isaac Goldberg⁵, Lorinda Chung⁶, Dinesh Khanna⁷, Zsuzsanna McMahan⁸, Michael Whitfield³ and Monique Hinchcliff⁹, ¹Northwestern Feinberg School of Medicine, Chicago, IL, ²UCSF, San Francisco, CA, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Northwestern University Division of Rheumatology, Chicago, IL, ⁵Wayne State University School of Medicine, Detroit, MI, ⁶Stanford University, Woodside, CA, ⁷University of Michigan, Ann Arbor, MI, ⁸UTHealth Houston Division of Rheumatology, Houston, TX, ⁹Yale School of Medicine, Westport, CT
Background/Purpose: It has become clear that classification by phenotype is insufficient to explain the heterogeneity in clinical progression for many rheumatic diseases. Systemic sclerosis (SSc)…

1
2
3
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.